Medivance: Climate Control for the Body

Physicians have long theorized that being able to precisely warm and cool patients, depending on their conditions and settings, would be beneficial in both cardiovascular and neurological procedures, and recent clinical evidence has shown temperature management to be even more important than initially thought.Medivance is looking to develop a non-invasive external temperature management system that is both simple to operate and suitable for a variety of settings for both precise warming and cooling. The company believes an external device avoids the risk of an invasive procedure and can be used easily by neurologists, who generally aren't comfortable inserting catheters.In striving to solve a difficult technology problem (external, non-invasive temperature management) with an easy-to-use device, Medivance is looking to avoid a problem that plagues many device companies--falling in love with complex, hard-to-operate technology. While a very sophisticated device may work effectively, a steep learning curve inhibits broad adoption because physicians are notoriously reluctant to adopt new technology unless it closely resembles current techniques. Medivance's system enables an anesthesiologist to regulate patient temperature without intruding on the surgical field and without heating up the OR, a win-win for surgeons.

by Stephen Levin

In 1997, veteran medical device inventor/entrepreneur Norman R. Weldon, having successfully launched and/or headed several cardiovascular companies including Cordis Corp....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.